ABIRA MEDICAL LABORATORIES, LLC v. BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES

CourtDistrict Court, D. New Jersey
DecidedOctober 30, 2024
Docket3:24-cv-00898
StatusUnknown

This text of ABIRA MEDICAL LABORATORIES, LLC v. BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES (ABIRA MEDICAL LABORATORIES, LLC v. BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES) is published on Counsel Stack Legal Research, covering District Court, D. New Jersey primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ABIRA MEDICAL LABORATORIES, LLC v. BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES, (D.N.J. 2024).

Opinion

NOT FOR PUBLICATION

UNITED STATES DISTRICT COURT DISTRICT OF NEW JERSEY

ABIRA MEDICAL LABORATORIES, LLC d/b/a GENESIS DIAGNOSTICS,

Plaintiff, Civil Action No. 24-00898 (GC) (RLS) v. OPINION BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES, et al.,

Defendants.

CASTNER, District Judge

THIS MATTER comes before the Court upon the Motion to Dismiss the Complaint pursuant to Federal Rules of Civil Procedure (Rules) 12(b)(1) and 12(b)(6) filed by Defendant Benefit Plan Administrators, Inc.1 (ECF No. 6.) Plaintiff opposed, and Defendant replied. (ECF Nos. 8 & 9.) The Court has carefully considered the parties’ submissions and decides the matter without oral argument pursuant to Rule 78(b) and Local Civil Rule 78.1(b). For the reasons set forth below, and other good cause shown, Defendant’s Motion is GRANTED. I. BACKGROUND

This is one of more than forty cases that Plaintiff Abira Medical Laboratories, LLC, has filed in the United States District Court for the District of New Jersey or had removed here from

1 Defendant asserts that it was incorrectly identified in Plaintiff’s Complaint as “BPA Bestlife Benefit Plan Administrators.” (ECF No. 6-3 at 5.) Plaintiff does not contest this assertion, the Superior Court of New Jersey since June 2023. See Abira Med. Lab’ys, LLC v. Avera Health Plans, Civ. No. 23-03465, 2024 WL 2721390, at *1 (D.N.J. May 28, 2024). Plaintiff “is a domestic limited liability company organized under the laws of the State of New Jersey.” (ECF No. 1-1 ¶ 6.) Defendant has its principal place of business in Roanoke, Virginia and is alleged to provide “health insurance services throughout New Jersey.” (Id. ¶ 7.)

Plaintiff alleges that it provided “laboratory services” to the “subscribers/members” of Defendant’s health insurance services. (Id. ¶¶ 7, 13.) Defendant, however, “regularly refused to pay and/or underpaid claims . . . submitted by [Plaintiff] or simply failed to respond in any way to numerous claims submitted by [Plaintiff]” for services it allegedly rendered to Defendant’s subscribers/members. The amount due for these services is alleged to total $145,940.00.2 (Id. ¶ 42.) Plaintiff accuses Defendant of “offer[ing] spurious explanations—obviously created from whole cloth” to justify its failure to pay Plaintiff for services that it rendered to Defendant’s members, including “lack of adequate claim information,” “untimely filing of claims,” “lack of coverage,” and “failure to meet conditions of coverage.” (Id. ¶¶ 2-4.) Plaintiff does not identify

the individual insureds/claimants in this case, the type of health insurance plans under which the insureds/claimants were covered, or any specific provisions in any plan that entitles the insureds/claimants to benefits from Defendant. Plaintiff asserts four causes of action against Defendant, other unidentified “affiliates,” and unnamed companies and persons: Count One for breach of contract; Count Two for breach of the implied covenant of good faith and fair dealing; Count Three for fraudulent misrepresentation, negligent misrepresentation, and equitable and promissory estoppel; and Count Four for violations of the New Jersey Consumer Fraud Act (NJCFA), N.J. Stat. Ann. § 56:8-2, under which Plaintiff

2 The Court has subject-matter jurisdiction over this matter under 28 U.S.C. § 1332. seeks treble damages for a total “in excess of $437,820.” (Id. ¶¶ 19-42.) This case was removed to this Court from the Superior Court of New Jersey, Mercer County, Law Division, based on diversity jurisdiction pursuant to 28 U.S.C. § 1332. (See ECF No. 1.) On March 21, 2024, Defendant moved to dismiss the Complaint pursuant to Rules 12(b)(1) and 12(b)(6). (ECF No. 6.) Plaintiff opposed on April 22, and Defendant replied on April 29.

(ECF Nos. 8 & 9.) II. LEGAL STANDARD

On a motion to dismiss for failure to state a claim upon which relief can be granted, courts “accept the factual allegations in the complaint as true, draw all reasonable inferences in favor of the plaintiff, and assess whether the complaint and the exhibits attached to it ‘contain enough facts to state a claim to relief that is plausible on its face.’” Wilson v. USI Ins. Serv. LLC, 57 F.4th 131, 140 (3d Cir. 2023) (quoting Watters v. Bd. of Sch. Directors of City of Scranton, 975 F.3d 406, 412 (3d Cir. 2020)). “A claim is facially plausible ‘when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.’” Clark v. Coupe, 55 F.4th 167, 178 (3d Cir. 2022) (quoting Mammana v. Fed. Bureau of Prisons, 934 F.3d 368, 372 (3d Cir. 2019)). When assessing the factual allegations in a complaint, courts “disregard legal conclusions and recitals of the elements of a cause of action that are supported only by mere conclusory statements.” Wilson, 57 F.4th at 140 (citing Oakwood Lab’ys LLC v. Thanoo, 999 F.3d 892, 903 (3d Cir. 2021)). The defendant bringing a Rule 12(b)(6) motion bears the burden of “showing that a complaint fails to state a claim.” In re Plavix Mktg., Sales Pracs. & Prod. Liab. Litig. (No. II), 974 F.3d 228, 231 (3d Cir. 2020) (citing Davis v. Wells Fargo, 824 F.3d 333, 349 (3d Cir. 2016)). III. DISCUSSION A. COUNTS ONE AND TWO—BREACH OF CONTRACT & BREACH OF IMPLIED COVENANT OF GOOD FAITH AND FAIR DEALING

Defendant argues that Plaintiff does not allege the identities or “the number of persons . . . to whom it provided services,” the “policy provision or other standards or protocols that were purportedly violated,” nor that “any of the members or subscribers in the health care plans administered by [Defendant] executed any assignments of benefits, giving Plaintiff the ability to collect insurance benefits payable to the members and/or subscribers.” (ECF No. 6-3 at 7.3) Plaintiff responds that it has alleged that it is an “authorized representative” of the unidentified insureds, citing Employee Retirement Income Security Act of 1974 (ERISA) regulation 29 C.F.R. § 2560.503-1(b)(4); and that Defendant “failed to pay for the laboratory services rendered in breach of Defendant’s agreement with the claimants (now represented by [Plaintiff]).” (ECF No. 8 at 16.) Plaintiff also argues that because Plaintiff “alleged that Defendants paid for some of the services rendered . . . thereby confirming the existence of an agreement between the parties via its course of conduct,” Plaintiff has sufficiently pled a claim for breach of contract. (Id. at 16-17.) The Court disagrees. First, nowhere in the Complaint does Plaintiff allege that it is an “authorized representative” of the currently unidentified insureds under ERISA regulation 29 C.F.R. § 2560.503-1(b)(4). In fact, the Complaint does not plead that the plans at issue are ERISA plans to which the regulation would be applicable. Further, courts have held that the regulation

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Weiss v. First Unum Life Insurance Company
482 F.3d 254 (First Circuit, 2007)
Wade v. Kessler Institute
798 A.2d 1251 (Supreme Court of New Jersey, 2002)
North Jersey Brain & Spine Center v. Aetna, Inc.
801 F.3d 369 (Third Circuit, 2015)
Joshua Watters v. Board of School Directors
975 F.3d 406 (Third Circuit, 2020)
Oakwood Laboratories LLC v. Bagavathikanun Thanoo
999 F.3d 892 (Third Circuit, 2021)
Davis v. Wells Fargo, U.S.
824 F.3d 333 (Third Circuit, 2016)
Mammana v. Fed. Bureau of Prisons
934 F.3d 368 (Third Circuit, 2019)
Crozier v. Johnson & Johnson Consumer Companies, Inc.
901 F. Supp. 2d 494 (D. New Jersey, 2012)
Angelo Clark v. Robert Coupe
55 F.4th 167 (Third Circuit, 2022)
Rhonda Wilson v. USI Insurance Services LLC
57 F.4th 131 (Third Circuit, 2023)

Cite This Page — Counsel Stack

Bluebook (online)
ABIRA MEDICAL LABORATORIES, LLC v. BPA BESTLIFE BENEFIT PLAN ADMINISTRATORS AND THEIR AFFILIATES, Counsel Stack Legal Research, https://law.counselstack.com/opinion/abira-medical-laboratories-llc-v-bpa-bestlife-benefit-plan-administrators-njd-2024.